Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 11/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25326936 | 0.89 | PDK1 (0.37) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25327299 | 0.89 | RIPK1 (0.45) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25325516 | 0.86 | RIPK1 (0.53) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25325076 | 0.83 | NR1H2 (0.43) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25325079 | 0.83 | NR1H2 (0.43) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25323657 | 0.83 | PDK1 (0.39) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25327211 | 0.81 | PRMT5 (0.39) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25324288 | 0.80 | POLB (0.45) | RIPK1SIGMAR1PRMT5WDR77 | |
| SCHEMBL25329557 | 0.79 | RIPK1 (0.43) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25910407 | 0.78 | PRMT5 (0.65) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | RIPK1 4782/4885PDK1 2026/4885PDK2 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.